Bifonazole
| |
Clinical data | |
---|---|
Trade names | Canespor, many others |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Topical |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard |
100.056.651 |
Chemical and physical data | |
Formula | C22H18N2 |
Molar mass | 310.392 g/mol |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
|
Bifonazole (trade name Canespor among many others[1]) is an imidazole antifungal drug used in form of ointments.
There are also combinations with carbamide for the treatment of onychomycosis.
Adverse effects
The most common side effect is a burning sensation at the application site. Other reactions, such as itching, eczema or skin dryness, are rare.[2]
Pharmacology
Mechanism of action
Bifonazole has a dual mode of action. It inhibits fungal ergosterol biosynthesis at two points, via transformation of 24-methylendihydrolanosterol to desmethylsterol, together with inhibition of HMG-CoA. This enables fungicidal properties against dermatophytes and distinguishes bifonazole from other antifungal drugs.[2][3]
Pharmacokinetics
Six hours after application, bifonazole concentrations range from 1000 µg/cm³ in the stratum corneum to 5 µg/cm³ in the papillary dermis.[2]
References
- ↑ International Drug Names: Bifonazole.
- 1 2 3 Haberfeld, H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Canesten Bifonazol-Creme.
- ↑ Berg, D; Regel, E; Harenberg, H. E.; Plempel, M (1984). "Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole". Arzneimittel-Forschung. 34 (2): 139–46. PMID 6372801.
- Lackner, T. E.; Clissold, S. P. (1989). "Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses". Drugs. 38 (2): 204–25. doi:10.2165/00003495-198938020-00004. PMID 2670516.